Additionally, CatS inhibitors have been shown to reduce inflammation by modulating macrophage activity and cytokine release, highlighting CatS as a potential therapeutic target in obesity-related inflammatory conditions [46]. This evidence concerns the gene PIMREG and obesity disorder.